For the roughly 795,000 Americans who have a stroke each year, one of the biggest fears is having another one. This month, a new kind of medicine joined the options doctors can use to lower that risk.
The U.S. Food and Drug Administration has approved asundexian, sold by Bayer under the brand name Sunharbo, to reduce the risk of another stroke in adults who recently had a certain type of ischemic stroke or a high-risk transient ischemic attack (TIA, sometimes called a “mini-stroke”). Bayer announced the approval on November 10. It is the first approved drug in a new class called Factor XIa inhibitors, and Bayer says it is the first of its kind approved anywhere in the world for this use.
What the study found
The approval was based on OCEANIC-STROKE, a large international trial with 12,327 participants. Everyone in the study took standard antiplatelet medicine (such as aspirin or a similar drug). Half also took asundexian, and half took a placebo.
- Over about two years, ischemic strokes were reduced by 26% in relative terms compared with antiplatelet therapy alone, according to Bayer and TCTMD, a cardiology news service. In absolute terms, that was a 2.2 percentage-point reduction.
- Rates of major bleeding were similar between the two groups, which is notable because stronger blood thinners usually raise bleeding risk.
- Gastrointestinal bleeding was somewhat higher with asundexian, and diarrhea was the most common side effect, TCTMD reported. Some patients had raised liver enzymes, most of them mild, according to Bayer.
The full results were published in The New England Journal of Medicine.
Who it is for, and who it is not for
The approval covers adults who have had a recent ischemic stroke that was not caused by a clot from the heart, or a high-risk TIA, and who are taking antiplatelet therapy. TCTMD reported several important limits:
- It is not approved for people with atrial fibrillation, a common heart rhythm problem that causes many strokes.
- It is not recommended for people with moderate or severe liver problems.
- It is not recommended with certain other medicines that can make it less effective.
Ashkan Shoamanesh, a lead investigator of the trial, called the approval “an important advance in secondary stroke prevention,” TCTMD reported.
Cost and access
Bayer lists the price at $748.50 for a 30-day supply, though what patients pay depends on their insurance. Bayer says some patients may qualify for free medicine through its patient assistance foundation, and shipments were expected to begin this month. Experts quoted by TCTMD said cost and insurance coverage may be the biggest barriers at first. The drug was approved in China last month and is under review in Europe and Japan.
Why it matters for families
Stroke is the second leading cause of death worldwide, and Bayer notes that about 1 in 10 people who survive this type of stroke have another within a year. If someone in your family has had a stroke or a TIA, this is a good time to ask their doctor about their prevention plan. This article is general information, not medical advice. Do not start, stop or change any medicine on your own; talk with your doctor about whether a new option fits your situation.
Remember the warning signs with the letters BE FAST: Balance loss, Eyes (vision changes), Face drooping, Arm weakness, Speech difficulty and Time to call 911. Fast treatment saves brain function and lives. Cold weather also adds strain on the heart; see our guide to protecting your heart in cold weather, and our earlier roundup that first noted this stroke breakthrough.
Read more: WHO Issues First Type 1 Diabetes Guidelines for Adults on World Diabetes Day
Has your family learned the stroke warning signs? Share what helped you remember them in the comments.
Sources: Bayer, “Bayer’s asundexian first FXIa inhibitor approved by U.S. Food and Drug Administration for secondary stroke risk reduction” (November 10, 2026); TCTMD, “Asundexian Is the First Factor XIa Inhibitor to Gain FDA Approval” (November 10, 2026); PharmTech, “PharmTech’s Weekly Roundup, November 13, 2026”.





Leave a Reply